Since the main trends, such as improvements in insulin sensitivity with pharmacological or dietary interventions and the adverse influence of metabolic syndrome on fertility outcomes, were consistently observed in the low-risk studies as well, the overall interpretations did not materially change. The gene discussed is INS; the disease is metabolic syndrome.